# Baekseok Culture University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/baekseok-culture-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 70 |
| Citations | 2,678 |
| City | Cheonan |
| Country | South Korea |
| Description | Baekseok Culture University is a research organisation in Cheonan, South Korea. OpenAlex records 285 works and 2,678 citations for it. 1 researchers list it as their most recent affiliation. |
| Homepage | http://www.bscu.ac.kr |
| OpenAlex ID | https://openalex.org/I323946660 |
| Researchers | 1 |
| ROR ID | https://ror.org/00jpxtg25 |
| Type | education |
| Works | 285 |

## University papers

Showing 12 of 15.

- [Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial](https://scholariq.org/papers/pembrolizumab-versus-docetaxel-for-previously-treated-pd-l1-positive-advanced/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Brigatinib versus Crizotinib in <i>ALK</i> -Positive Non–Small-Cell Lung Cancer](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-i-alk-i-positive-non-small-cell-lung-cancer/)
- [Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations](https://scholariq.org/papers/tepotinib-in-non-small-cell-lung-cancer-with-i-met-i-exon-14-skipping-mutations/)
- [First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung](https://scholariq.org/papers/first-signal-first-line-single-agent-iressa-versus-gemcitabine-and-cisplatin/)
- [Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/osimertinib-for-pretreated-egfr-thr790met-positive-advanced-non-small-cell-lung/)
- [Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study](https://scholariq.org/papers/amivantamab-in-egfr-exon-20-insertion-mutated-non-small-cell-lung-cancer/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study](https://scholariq.org/papers/osimertinib-plus-savolitinib-in-patients-with-egfr-mutation-positive-met/)
- [Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-alk-inhibitor-naive-advanced-alk-positive-nsclc/)
- [Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial](https://scholariq.org/papers/brigatinib-versus-crizotinib-in-advanced-alk-inhibitor-naive-alk-positive-non/)
- [Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis](https://scholariq.org/papers/osimertinib-versus-platinum-pemetrexed-for-patients-with-egfr-t790m-advanced/)

## University researchers

- [Ji‐Youn Han](https://scholariq.org/researchers/ji-youn-han/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.